+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07486869

Study of Emapalumab for Treating Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

Led by University of Miami · Updated on 2026-08-25

5

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating emapalumab as a treatment for anti-MDA5 antibody positive rapidly progressive interstitial lung disease MDA5 RP-ILD, a severe lung condition often linked with dermatomyositis and related diseases. This phase 2 proof of concept study aims to determine if emapalumab, a drug currently used for macrophage activation syndrome, may help patients with this lung disease that shares similar immune system features. Participants in this study will receive intravenous emapalumab starting with a 6 mgkg dose on Day 1, followed by 3 mgkg every three days for two weeks, and then 3 mgkg twice weekly for an additional two weeks. The total treatment period is 12 weeks. This regimen is designed to assess the drugs effects over time on lung function and disease progression. During the study, participants will undergo assessments including oxygen requirement measurements, lung function tests such as Forced Vital Capacity FVC and Diffusing Capacity for Carbon Monoxide DLCO, and chest CT scans at baseline, 4 weeks, and 12 weeks. Blood tests will monitor ferritin and MDA5 antibody levels, and researchers will track any new infections during treatment. The primary goal is to observe changes in lung function and imaging findings to evaluate the treatments impact over the 12-week period.

CONDITIONS

Brief Title

Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Research Team

K

Kelly Corbitt, D.O.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here